Objective-Lysophosphatidylcholine (LPC), a major phospholipid component of oxidized low density lipoprotein, has been demonstrated to induce multiple functional alterations of vasculature that are potentially involved in atherosclerosis. Recently, an orphan G-protein-coupled receptor, G2A, has been identified as a high-affinity receptor for LPC.
was expressed predominantly in lymphoid tissues and cells. 11 Little is known about the expression of G2A in vascular cells, including monocytes/macrophages, smooth muscle cells, and endothelial cells, and no studies on the expression of G2A in atherosclerotic lesions have been reported. Resolving these issues is important for elucidating the, as yet, completely unknown function of G2A.
In the present study, we performed immunohistochemistry by using an anti-G2A antibody to investigate whether or not G2A was expressed in atherosclerotic lesions of apoE-deficient mice and Watanabe heritable hyperlipidemic (WHHL) rabbits. In both animal models, infiltrating macrophages within atherosclerotic lesions abundantly expressed G2A. Interestingly, in human coronary arteries, G2A staining was observed in lipid-rich plaques, whereas none of the fibrous plaques showed G2A immunoreactivity. We also examined whether or not the cardiovascular cells express G2A and demonstrated that mRNA and protein of G2A are highly expressed in human and murine monocytes/macrophages. These results suggest the possible involvement of G2A in the formation and progression of atherosclerotic lesions.
Methods

Immunohistochemistry
Aortic roots and thoracic aortas were isolated from apoE-deficient mice (nϭ5) fed a western-type diet for 8 weeks and homozygous WHHL rabbits (nϭ2) aged 3 months, respectively. All procedures were conducted according to the Guidelines for Animal Experimentation at Kobe University School of Medicine. Human coronary arteries were obtained from 19 autopsy cases (aged 29 to 92 years) after informed consent was given by their families. Segments were fixed in 10% neutral buffered formalin and then frozen in OCT compound (Tissue-Tek). Serial cryostat sections (6 m thick) were preincubated with 0.5% hydrogen peroxide in methanol. The sections were blocked with carrier protein (DAKO) and subsequently incubated with goat polyclonal anti-G2A antibody (Santa Cruz, 1:50 dilution), rat monoclonal anti-mouse macrophage antibody (MOMA2, Biosource; 1:20 dilution), mouse monoclonal anti-rabbit macrophage antibody (RAM11, DAKO; 1:30 dilution), mouse monoclonal anti-human CD68 antibody (KP-1, DAKO; 1:100 dilution), or mouse monoclonal anti-human smooth muscle ␣-actin antibody (1A4, Sigma Chemical Co; 1:400 dilution). After they were washed with PBS, the sections were incubated with biotinylated specific immunoglobulins (DAKO) followed by streptavidin-horseradish peroxidase conjugate (DAKO). After color development with 0.03% diaminobenzidine, the sections were counterstained with Mayer's hematoxylin.
Double-Labeling Immunofluorescence
The sections of human coronary arteries were incubated with anti-G2A antibody and anti-human CD68 antibody, followed by incubation with Texas red-conjugated swine anti-goat IgG (EY Laboratories) and FITC-conjugated sheep anti-mouse immunoglobulins (Amersham). The samples were examined by a laser scanning confocal imaging system (MRC-1024, Bio-Rad Laboratories). 12
Cell Culture
Human monocyte-derived macrophages were prepared as previously described. 13 Peripheral blood mononuclear cells were isolated from whole blood of normal human subjects by Ficoll-Paque density gradient centrifugation. After they were washed with PBS, the cells were plated in 35-mm dishes and allowed to adhere to the dishes for 2 hours in RPMI 1640 medium (GIBCO-BRL) supplemented with 10% heat-inactivated human serum. After nonadherent cells were discarded, premature macrophages were further incubated for 7 days in RPMI 1640 medium containing 10% human serum to differentiate into mature macrophages. The medium was replaced every 3 days. Mouse peritoneal macrophages were collected by peritoneal lavage with PBS from mice given an intraperitoneal injection of 4% thioglycollate in PBS. The cells were cultured in RPMI 1640 medium containing 10% FBS. A human monocytic cell line (THP-1), a human T-cell line (Jurkat T cells), and a murine monocyte/ macrophage cell line (J774A.1) were obtained from the American Type Culture Collection and cultured in RPMI 1640 medium containing 10% FBS. Human coronary artery smooth muscle cells and human umbilical vein endothelial cells were purchased from Clonetics.
Reverse Transcription-Polymerase Chain Reaction
G2A mRNA expression was analyzed by using reverse transcription (RT)-polymerase chain reaction (PCR) as described previously. 9 In brief, the first-strand cDNAs were synthesized from total mRNA isolated from cultured cells with the use of the manufacturer's kit (RETROscript, Ambion). Aliquots of cDNA were amplified with Ex-Taq DNA polymerase (Takara) with the use of human G2Aspecific primers, 5Ј-CGG TGG TTG TCA TCT TCC TA-3Ј (forward) and 5Ј-TTA GCG GCC GCT CAG CAG GAC TCC TCA ATC AG-3Ј (reverse), or murine G2A-specific primers, 5Ј-TAG CGG TCG CAG GAA ATG CAG-3Ј (forward) and 5Ј-CAG GAC TGG CTT GGG TCA TT-3Ј (reverse). 11 Primers for the amplification of GAPDH, 5Ј-ACC ACA GTC CAT GCC ATC AC-3Ј (forward) and 5Ј-TCC ACC ACC CTG TTG CTG TA-3Ј (reverse), were used as an internal control. PCR products were analyzed on a 1.5% agarose gel containing ethidium bromide and photographed.
Immunoblotting
Cells were lysed in a buffer (50 mmol/L Tris/HCl [pH 7.4], 50 mmol/L NaCl, 5 mmol/L EDTA, 0.5% Triton X-100, 0.5% NP-40, 10 g/mL leupeptin, 10 g/mL aprotinin, 10 mmol/L NaF, and 1 mmol/L phenylmethylsulfonyl fluoride). Immunoblotting was performed as described 6, 9 by using an anti-G2A antibody (1:500 dilution).
Results
Expression of G2A in Atherosclerotic Lesions of ApoE-Deficient Mice and WHHL Rabbits
Immunohistochemistry with a specific anti-G2A antibody was used to examine the G2A expression in atherosclerotic lesions. Accumulating lipids within atherosclerotic plaques in the aortic root of apoE-deficient mice were stained with Sudan III ( Figure 1A) . Foam cell lesions within atherosclerotic plaques were positive for G2A ( Figure 1B) . When the primary antibody was replaced with a nonimmune goat IgG, no reactivity was detected ( Figure 1C ). Immunohistochemistry using cell-specific antibodies revealed that the majority of the G2A-expressing cells were positive for anti-mouse macrophage antibody ( Figure 1D ) but not for anti-human smooth muscle ␣-actin antibody ( Figure 1E ). Consistently, macrophages, which infiltrated into the subendothelial space, expressed G2A in atherosclerotic lesions at the aortas of WHHL rabbits (Figure 2A through 2C ). Immunoreactivity of G2A was not detected in nonatherosclerotic lesions ( Figure 2D ).
Expression of G2A in Human Coronary Atherosclerotic Plaques
We next examined the G2A expression in human coronary arteries. In lipid-rich plaques, G2A expression was observed around the lipid core and at the shoulder region ( Figure 3A and 3E), where it colocalized with macrophage immunoreactivity ( Figure 3C and 3G ), but the expression pattern of G2A did not overlap the expression of smooth muscle ␣-actin ( Figure 3D and 3H) or CD3, a marker for T lymphocytes (results not shown). When the primary antibody was replaced with a nonimmune goat IgG, no reactivity was detected ( Figure 3B and 3F ). Immunoreactivity of neither G2A nor macrophage was detected in fibrous plaques that demonstrated staining with anti-human smooth muscle ␣-actin antibody ( Figure 3G through 3I) . None of the nonatherosclerotic coronary arteries with diffuse intimal thickening showed G2A immunoreactivity (results not shown). Double-labeling immunofluorescence analysis further confirmed colocalization of G2A expression with macrophage immunoreactivity (Figures 3L through 3N ).
Expression of G2A in Cardiovascular Cells
Human monocytic THP-1 and monocyte-derived macrophages express G2A mRNA expression (please see online Figure IA , available at http://atvb.ahajournals.org). Weak mRNA expression of G2A was observed in Jurkat T cells, human coronary artery smooth muscle cells, and human umbilical vein endothelial cells. Murine macrophage J774A.1 as well as thioglycollate-elicited peritoneal macrophages abundantly expressed G2A mRNA, whereas no significant expression was detected in murine endothelial cells (PY4.1) and fibroblasts (NIH 3T3) or in rat aortic smooth muscle cells (please see online Figure IB ). Although rat G2A has not yet been cloned, the present RT-PCR analysis using murine primers was likely able to detect rat G2A cDNA, because a single band with the same molecular size was detected in the RT-PCR product of rat spleen cells.
A high level of the G2A protein was detected in human and murine monocytes/macrophages, whereas no significant staining was detectable in other tested cells, indicating the higher expression level of G2A protein in monocytes and macrophages (please see online Figure II , available at http:// atvb.ahajournals.org). These results clearly demonstrated that G2A is abundantly expressed in monocytes/macrophages.
Discussion
Although it has been reported that G2A is expressed predominantly in T and B lymphocytes, 11 little is known about the expression of G2A in cardiovascular cells. In the present study, we demonstrated that G2A was highly expressed in cultured human and murine monocytic cell lines and macrophages. The potential physiological role of G2A in these cells remains unclear. G2A was originally identified as a Bcl-Ablinducible gene. 11 Ectopic expression of G2A antagonizes the transformation of Rat-1 fibroblasts by Bcl-Abl and results in the accumulation of cells within G2/M. By contrast, another group independently isolated G2A and showed that ectopic expression of G2A induces oncogenic transformation of NIH 3T3 fibroblasts. 14 Thus, whether G2A may promote or antagonize cell growth may depend on the presence of other signals and/or cell-type differences. Indeed, it has been reported that LPC has biphasic effects on cell growth, ie, a stimulatory effect for macrophages 15 and vascular smooth muscle cells 16 and an inhibitory effect for endothelial cells, 6 but it remains to be determined whether G2A may exhibit a growth-promoting or growth-antagonizing function in the vascular cells.
As reported previously, binding of LPC with G2A can induce calcium mobilization and mitogen-activated protein kinase activation via a pertussis toxin-sensitive pathway. 14 Oxidized LDL is known to increase intracellular calcium concentration and activate mitogen-activated protein kinase. It was interesting to discover that these effects of oxidized LDL are mediated by LPC via G2A. However, it remains unknown whether G2A can recognize LPC associated with oxidized LDL. Besides monocytes/macrophages, vascular endothelial and smooth muscle cells play an important role in atherogenesis. However, the expression of G2A was not detected in these cells. Another GPCR, GPR4, has been also identified as a receptor for LPC. 17 It is possible that these GPR4 and/or other unidentified receptors may be expressed by vascular endothelial and smooth muscle cells. Further investigations are necessary to solve these issues.
Immunohistochemistry revealed that G2A is highly expressed in infiltrating macrophages within atherosclerotic lesions. The pathological role of G2A in atherosclerotic lesions remains unknown. It is suggested that G2A may play a role as a sensor of LPC levels at sites of inflammation, thus limiting the expansion of tissue-infiltrating cells and the progression to overt autoimmune disease, inasmuch as it has been reported that T lymphocytes from G2A-deficient mice exhibit hyperproliferative responses to antigen receptors that are cross-linked with stimulation. 18 As for monocytes/macrophages, it has been demonstrated that LPC is chemotactic for monocytes, 19 stimulates monocyte production of heparinbinding epidermal growth factor-like growth factor, a potent mitogen for smooth muscle cells, 20 and increases DNA synthesis in macrophages. 15 Therefore, we speculate that LPC might induce the recruitment of monocytes and stimulate the proliferation of macrophages and smooth muscle cells through G2A in atherosclerotic lesions, resulting in the progression of atherosclerotic lesion formation. Thus, to specifically interrupt G2A activation by LPC might develop into a novel therapeutic strategy to alter the development of atherosclerotic lesions. 
